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background:  Over the last 3 years, SC administered evolocumab, a fully human monoclonal antibody to PCSK9, has been shown to 
robustly reduce LDL-C and be well tolerated. We now report the pooled safety analysis with evolocumab in patients participating in phase 
2 or 3 randomized and placebo/comparator-controlled trials and in open-label extension trials where there was a standard of care control 
group.
Methods:  Clinical and laboratory adverse event (AE) data were pooled from 6026 patients in 12 phase 2 and 3 studies and from 4465 
patients in two extension studies emanating from those parent studies. Adverse events were calculated separately for the phase 2/3 parent 
studies and the open-label extension studies.
Results:  Overall AE rates were similar between evolocumab and control in both parent studies (51.1% vs 50.0 %) and Year 1 of extension 
studies (65.4% vs 61.1%) (Table), as were those for SAEs inclusive of myalgia. No relationship between AEs and dose/frequency was 
observed (data not shown). No neutralizing antibodies were detected. Creatine kinase and liver enzyme elevations were infrequent and 
similar between groups. Adverse event profiles were similar between parent studies and Year 1 of the extension studies.
conclusion:  Although of relatively short duration, this large pooled analysis from over 6000 patients in phase 2 and 3 trials with 
evolocumab demonstrated no increase in clinical or laboratory SAEs or AEs compared to control/standard of care groups.
Integrated Parent Studies Integrated Interim Extension Studies Year 1
Control
(N = 2080)
Evolocumab
(N = 3946)
Standard of Care
(N = 1489)
Evolocumab
(N = 2976)
Any AE, n (%) 1599 (50.0) 2016 (51.1) 910 (61.1) 1946 (65.4)
Five most common AEs in parent studies, n (%)
Nasopharyngitis 99 (4.8) 231 (5.9) 128 (8.6) 264 (8.9)
Upper respiratory tract infection 56 (2.7) 127 (3.2) 64 (4.3) 153 (5.1)
Headache 66 (3.2) 120 (3.0) 28 (1.9) 98 (3.3)
Back pain 57 (2.7) 117 (3.0) 47 (3.2) 113 (3.8)
Myalgia 55 (2.6) 98 (2.5) 38 (2.6) 84 (2.8)
Five most common AEs in extension studies not represented in most common parent study AEs, n (%)
Arthralgia 45 (2.2) 91 (2.3) 44 (3.0) 120 (4.0)
Hypertension 26 (1.3) 56 (1.4) 57 (3.8) 104 (3.5)
Serious AEs, n (%)
Any 43 (2.1) 110 (2.8) 100 (6.7) 197 (6.6)
AEs leading to study drug discontinuation, n (%)
Any 48 (2.3) 75 (1.9) N/A 68 (2.3)
AEs of interest, n (%)
Injection-site reactions 63 (3.0) 130 (3.3) N/A 122 (4.1)
Muscle-related AEs 98 (4.7) 198 (5.0) 84 (5.6) 175 (5.9)
Neurocognitive 6 (0.3) 5 (0.1) 3 (0.2) 25 (0.8)
Creatine kinase >5x ULN 14 (0.7) 27 (0.7) 17 (1.2) 17 (0.6)
ALT or AST >3x ULN 20 (1.0) 17 (0.4) 18 (1.2) 30 (1.0)
Injection-site reactions are identified using the injection site reaction high-level term. Potential muscle-related events are identified using the rhabdomyolysis-
myopathy broad Standard MedDRA Queries. Neurocognitive events are identified using the deliria (including confusion), cognitive and attention disorders and 
disturbances, dementia and amnestic conditions, disturbances in thinking and perception, and mental impairment disorders high-level group terms. Control includes 
placebo and ezetimibe treatment groups. AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal
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